Uromodulin to Osteopontin Ratio in Deceased Donor Urine Is Associated With Kidney Graft Outcomes
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: Deceased-donor kidneys experience extensive injury, activating adaptive and maladaptive pathways therefore impacting graft function. We evaluated urinary donor uromodulin (UMOD) and osteopontin (OPN) in recipient graft outcomes.
METHODS: Primary outcomes: all-cause graft failure (GF) and death-censored GF (dcGF). Secondary outcomes: delayed graft function (DGF) and 6-month estimated glomerular filtration rate (eGFR). We randomly divided our cohort of deceased donors and recipients into training and test datasets. We internally validated associations between donor urine UMOD and OPN at time of procurement, with our primary outcomes. The direction of association between biomarkers and GF contrasted. Subsequently, we evaluated UMOD:OPN ratio with all outcomes. To understand these mechanisms, we examined the effect of UMOD on expression of major histocompatibility complex II in mouse macrophages.
RESULTS: Doubling of UMOD increased dcGF risk (adjusted hazard ratio [aHR], 1.1; 95% confidence interval [CI], 1.02-1.2), whereas OPN decreased dcGF risk (aHR, 0.94; 95% CI, 0.88-1). UMOD:OPN ratio ≤3 strengthened the association, with reduced dcGF risk (aHR, 0.57; 0.41-0.80) with similar associations for GF, and in the test dataset. A ratio ≤3 was also associated with lower DGF (aOR, 0.73; 95% CI, 0.60-0.89) and higher 6-month eGFR (adjusted β coefficient, 3.19; 95% CI, 1.28-5.11). UMOD increased major histocompatibility complex II expression elucidating a possible mechanism behind UMOD's association with GF.
CONCLUSIONS: UMOD:OPN ratio ≤3 was protective, with lower risk of DGF, higher 6-month eGFR, and improved graft survival. This ratio may supplement existing strategies for evaluating kidney quality and allocation decisions regarding deceased-donor kidney transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Transplantation - 105(2021), 4 vom: 01. Apr., Seite 876-885 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mansour, Sherry G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.07.2021 Date Revised 02.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/TP.0000000000003299 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313446342 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313446342 | ||
| 003 | DE-627 | ||
| 005 | 20231225150605.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/TP.0000000000003299 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313446342 | ||
| 035 | |a (NLM)32769629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mansour, Sherry G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uromodulin to Osteopontin Ratio in Deceased Donor Urine Is Associated With Kidney Graft Outcomes |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2021 | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Deceased-donor kidneys experience extensive injury, activating adaptive and maladaptive pathways therefore impacting graft function. We evaluated urinary donor uromodulin (UMOD) and osteopontin (OPN) in recipient graft outcomes | ||
| 520 | |a METHODS: Primary outcomes: all-cause graft failure (GF) and death-censored GF (dcGF). Secondary outcomes: delayed graft function (DGF) and 6-month estimated glomerular filtration rate (eGFR). We randomly divided our cohort of deceased donors and recipients into training and test datasets. We internally validated associations between donor urine UMOD and OPN at time of procurement, with our primary outcomes. The direction of association between biomarkers and GF contrasted. Subsequently, we evaluated UMOD:OPN ratio with all outcomes. To understand these mechanisms, we examined the effect of UMOD on expression of major histocompatibility complex II in mouse macrophages | ||
| 520 | |a RESULTS: Doubling of UMOD increased dcGF risk (adjusted hazard ratio [aHR], 1.1; 95% confidence interval [CI], 1.02-1.2), whereas OPN decreased dcGF risk (aHR, 0.94; 95% CI, 0.88-1). UMOD:OPN ratio ≤3 strengthened the association, with reduced dcGF risk (aHR, 0.57; 0.41-0.80) with similar associations for GF, and in the test dataset. A ratio ≤3 was also associated with lower DGF (aOR, 0.73; 95% CI, 0.60-0.89) and higher 6-month eGFR (adjusted β coefficient, 3.19; 95% CI, 1.28-5.11). UMOD increased major histocompatibility complex II expression elucidating a possible mechanism behind UMOD's association with GF | ||
| 520 | |a CONCLUSIONS: UMOD:OPN ratio ≤3 was protective, with lower risk of DGF, higher 6-month eGFR, and improved graft survival. This ratio may supplement existing strategies for evaluating kidney quality and allocation decisions regarding deceased-donor kidney transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class II |2 NLM | |
| 650 | 7 | |a SPP1 protein, human |2 NLM | |
| 650 | 7 | |a UMOD protein, human |2 NLM | |
| 650 | 7 | |a Uromodulin |2 NLM | |
| 650 | 7 | |a Osteopontin |2 NLM | |
| 650 | 7 | |a 106441-73-0 |2 NLM | |
| 700 | 1 | |a Liu, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Yaqi |e verfasserin |4 aut | |
| 700 | 1 | |a Reese, Peter P |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Isaac E |e verfasserin |4 aut | |
| 700 | 1 | |a El-Achkar, Tarek M |e verfasserin |4 aut | |
| 700 | 1 | |a LaFavers, Kaice A |e verfasserin |4 aut | |
| 700 | 1 | |a Obeid, Wassim |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenberg, Avi Z |e verfasserin |4 aut | |
| 700 | 1 | |a Daneshpajouhnejad, Parnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Doshi, Mona D |e verfasserin |4 aut | |
| 700 | 1 | |a Akalin, Enver |e verfasserin |4 aut | |
| 700 | 1 | |a Bromberg, Jonathan S |e verfasserin |4 aut | |
| 700 | 1 | |a Harhay, Meera N |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Muthukumar, Thangamani |e verfasserin |4 aut | |
| 700 | 1 | |a Schröppel, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Pooja |e verfasserin |4 aut | |
| 700 | 1 | |a El-Khoury, Joe M |e verfasserin |4 aut | |
| 700 | 1 | |a Weng, Francis L |e verfasserin |4 aut | |
| 700 | 1 | |a Thiessen-Philbrook, Heather R |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Chirag R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation |d 1963 |g 105(2021), 4 vom: 01. Apr., Seite 876-885 |w (DE-627)NLM000023787 |x 1534-6080 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:876-885 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/TP.0000000000003299 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2021 |e 4 |b 01 |c 04 |h 876-885 | ||